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ABSTRACT
Objective To compare physical disability, mental health, 
fatigue and health- related quality of life (HRQoL) across 
juvenile idiopathic arthritis (JIA) categories in adulthood 
and between JIA and adult- onset rheumatic diseases.
Methods Cross- sectional analysis nested in a cohort of 
adult patients with JIA registered in the Rheumatic Diseases 
Portuguese Register ( Reuma. pt). Physical disability (Health 
Assessment Questionnaire—Disability Index), mental health 
symptoms (Hospital Anxiety and Depression Scale), fatigue 
(Functional Assessment of Chronic Illness Therapy—Fatigue 
Scale (FACIT- F)) and HRQoL (EuroQol- 5D (EQ5D) and Short 
Form (SF- 36)) were compared across JIA categories. Patients 
with polyarticular JIA and enthesis- related arthritis (ERA) JIA 
were compared respectively to patients with rheumatoid 
arthritis (RA) and spondyloarthritis (SpA), matched for gender 
and age, adjusted for disease duration and activity.
Results 585 adult patients with JIA were included. 
Comparison across JIA categories showed that persistent 
oligoarthritis and patients with ERA reported a higher score in 
EQ5D and SF- 36 physical component when compared with 
other JIA categories.
Polyarticular JIA reported less disability and fatigue than 
patients with RA (median Health Assessment Questionnaire of 
0.25 vs 0.63; p<0.001 and median FACIT- F score 42 vs 40 ; 
p=0.041). Polyarticular JIA had also better scores on EQ5D and 
all domains of SF- 36, than patients with RA. Patients with ERA 
reported less depression and anxiety symptoms (0% vs 14.8%; 
p=0.003% and 9% vs 21.3%; p=0.002) and less fatigue 
symptoms (45 vs 41; p=0.01) than patients with SpA.
Conclusion Persistent oligoarticular JIA and ERA are the 
JIA categories in adulthood with better HRQoL. Overall, adult 
polyarticular and patients with ERA JIA have lower functional 
impairment and better quality- of- life than patients with RA and 
SpA.
INTRODUCTION
The term juvenile idiopathic arthritis (JIA) is 
used to designate a very heterogeneous group 
of chronic inflammatory diseases with onset 
before 16 years old that actually correspond 
to distinct diseases with different prognosis.1 
The course of these diseases is highly variable 
but several studies estimate that 37%–63% 
of the adults who have had a diagnosis of JIA 
in childhood maintain active disease.2–6 For 
these patients, as well as for the patients that 
Key messages
What is already known about this subject?
 ► We currently know that health- related quality of life 
(HRQoL) of patients with juvenile idiopathic arthritis 
(JIA) in adulthood is lower than for the general pop-
ulation. Less is known about HRQoL of patients with 
JIA in adulthood compared with adult- onset rheu-
matic diseases.
What does this study add?
 ► This study, that compared for the first time, different 
patient reported outcomes regarding mental health 
symptoms, fatigue and HRQoL across JIA categories 
in adulthood and also adult patients with JIA with 
adult- onset rheumatic diseases, showed that adult 
polyarticular and patients with ERA JIA have an 
overall better quality of life than patients with rheu-
matoid arthritis and spondyloarthritis.
How might this impact on clinical practice or 
further developments?
 ► We believe that understanding the way these juve-
nile diseases impact the mental health and HRQoL in 
adulthood could help to develop strategies to enable 
multidisciplinary responses in order to improve cop-
ing and general health promotion of these patients.
 ► In our view these results will be of interest to both 
paediatric and adult rheumatologists who are in-
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achieve disease remission but experience damage caused 
by JIA or medication side effects, the disease has impact 
on their health- related outcomes.5 Even though efforts 
have been made to determine predictors of long- term 
outcomes regarding physical disability, psychological and 
health- related quality of life (HRQoL) in JIA,4 5 7 8 the 
global burden of the disease is still not accurately estab-
lished.
Patient- reported outcomes (PROs) are crucial for 
patient- centred healthcare as they can directly measure 
several dimensions of patient’s health.9 Despite the 
common use of PROs in adult patients with JIA in clinical 
practice, we still do not have a complete knowledge of 
these outcomes in every dimensions. What we currently 
know is that HRQoL of patients with JIA in adulthood 
is lower than for the general population,3 5 10 similarly 
to several adult- onset rheumatic diseases.11 12 However 
less is known about HRQoL of adult patients with JIA 
compared with patients with other rheumatic diseases 
with adult onset.13 The same is true for the long- term 
psychological effects of JIA in adulthood, with significant 
morbidity being reported14 but without substantial data 
that compares it with adult- onset rheumatic diseases. Of 
note, we have previously shown that most adult polyar-
ticular JIA and enthesis- related arthritis (ERA) patients 
fulfil classification criteria for rheumatoid arthritis (RA) 
and spondyloarthritis (SpA) and maintain disease activity 
and functional impairment in adulthood.4
The aims of this study were to evaluate PROs (namely 
physical disability, mental health, fatigue and HRQoL) 
across different JIA categories in adulthood, compare 
these PROs between polyarticular adult patients with JIA 
and patients with RA and between adult patients with 
ERA and patients with adult- onset SpA.
METHODS
Study design and patient selection
This is a cross- sectional analysis nested in a cohort study 
with the following inclusion criteria: patients with JIA 
according to the 2001 revised International League of 
Associations for Rheumatology (ILAR) criteria,1 regis-
tered in the Rheumatic Diseases Portuguese Register 
( Reuma. pt),15 that at the time of data extraction 
(December 2019) were older than 18 years old, had a 
disease duration greater than 5 years and available data 
in adulthood.
 Reuma. pt was developed by the Portuguese Society of 
Rheumatology, became active in June 2008 and includes 
patients with JIA, RA, SpA and several other rheumatic 
diseases. Specifically, 1955 patients with JIA have been 
registered so far in  Reuma. pt.16
At the time of this analysis, a total of 650 adult patients 
with JIA were registered. Thirty of them were excluded 
due to the lack of data registered in adulthood. Of the 
620 patients eligible for this study only 585 had complete 
data registered regarding ILAR category at onset and 
were included (figure 1). From these 585 patients, 279 
patients were registered in childhood and 306 patients 
were introduced in  Reuma. pt already in adulthood and 
classified retrospectively according to the ILAR classifica-
tion. Data before 2008 was registered retrospectively and 
prospectively thereafter.
Patients with polyarticular JIA course (extended 
oligoarthritis, rheumatoid factor (RF) negative and RF 
positive polyarthritis) and with ERA were compared, 
respectively, to the same number of controls constituted 
by patients with adult- onset RA and SpA, registered in 
Reuma. pt, matched for gender and age group. In order 
to achieve this, the 9046 RA and 4827 patients with adult- 
onset SpA registered in  Reuma. pt up to the date of data 
capture, were grouped according to their gender and age 
group (18–39 years old; 40–59 years old and ≥60 years 
old) and then randomised in order to match by gender 
and age group the polyarticular JIA course and patients 
with ERA, respectively.
Registry of patient data in  Reuma. pt occurred after 
signed informed consent was obtained. This study was 
approved by the scientific committee of  Reuma. pt and 
by the ethics committee of Lisbon Academic Medical 
Centre.  Reuma. pt was approved by the National Data 
Protection Authority and by local ethics committees 
Figure 1 Disposition of adult patients with JIA registered in 
Reuma.pt eligible for this study. ILAR, International League 
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of the participating centres. The study was conducted 
according to the Declaration of Helsinki.
Clinical data collection
The following information registered at the time of 
patient’s last visit available at the moment of data expor-
tation (December 2019) was obtained: sex, ethnicity, 
age at last visit, years of education, employment status 
(employed, unemployed, retired and early retirement 
due to JIA induced disability as certified by a board of 
physicians), ILAR category at onset, age at disease onset, 
disease duration (years), presence of RF, anti- citrullinated 
protein antibodies (ACPA), antinuclear antibodies 
(considered positive if titres ≥1/160) and human leuko-
cyte antigen B27 (HLA B27), number of active joints, 
patient and physician’s global assessment of disease 
activity (0–10), back pain (0–10), morning stiffness 
intensity (0–10), erythrocyte sedimentation rate (ESR, 
mm/first hour) and C reactive protein level (CRP, mg/
dL), extra- articular manifestations, Health Assessment 
Questionnaire (HAQ) score, Juvenile Arthritis Damage 
Index (JADI) score, current and previous therapy with 
corticosteroids, disease- modifying antirheumatic drugs 
(DMARD) and biological therapy.
In the  Reuma. pt JIA protocol there is a field asking the 
physician to check if the adult patient fulfils classification 
criteria for any of the following adult rheumatic diseases: 
RA; ankylosing spondylitis (AS); psoriatic arthritis (PsA); 
undifferentiated spondyloarthritis; adult- onset Still disease 
(AOSD); non- classifiable. Data registered in this  Reuma. pt 
field were also exported.
Juvenile Arthritis Disease Activity Score,17 shows limita-
tions for the assessment of adults with JIA, particularly those 
with predominant axial disease. For that reason we opted to 
apply disease activity scores specific for adult- onset rheumatic 
diseases as described in Oliveira- Ramos et al.4 Patients were 
classified as having inactive disease based on cut- offs defined 
for each index: Disease Activity Score (DAS) 28 <2.618–20 for 
patients who could be classified as RA; DAS 44, and DAS 
44 <1.621 22 for PsA and peripheral patients with SpA; AS 
DAS <1.323 for patients who fulfil classification criteria now 
in adulthood for AS. Patients classified as AOSD or with non- 
classifiable adult rheumatic disease were considered to have 
inactive disease if they had: no active arthritis; no fever, rash, 
serositis, splenomegaly or generalised lymphadenopathy 
attributable to JIA; no active uveitis; normal ESR and/or 
CRP; a physician’s global assessment of disease activity rated 
at the best score possible.24 The disease activity was measured 
at the same time of PROs’ fulfilment.
In the absence of a validated score for evaluation of 
damage in adults with JIA, we opted to use JADI, as a more 
comprehensive way of assessing articular damage (JADI- A) 
and extra- articular damage (JADI- E).25
Patient-reported outcomes variables
In every clinical visit registered in  Reuma. pt, patients are 
asked to fulfil PROs, with a minimum frequency of every 6 
months for the assessment of functional status and every year 
for questionnaires assessing HRQoL. The functional status 
was measured by Health Assessment Questionnaire—Disa-
bility Index,26 obtained at the last visit registered. For the 
purpose of this analysis, mild disability was considered for 
HAQ scores >0 and ≤0.5, moderate disability >0.5 and ≤1.5 
and severe disability >1.5.27
HRQoL was assessed using the 3- level version of Euro-
Qol- 5D (EQ5D)28 and Medical Outcomes Study 36- item 
Short Form (SF- 36).29
In order to evaluate fatigue, the results of the Func-
tional Assessment of Chronic Illness Therapy—Fatigue 
Scale30 were obtained
Anxiety and depression symptoms of our study popu-
lation were measured using results from the Hospital 
Anxiety and Depression Scale (HADS).31 Scores between 
0 and 7 represent ‘no case’; 8–10 indicate ‘possible case’ 
and 11–21 suggest a ‘probable case of anxiety/depres-
sion’.14 32 We considered the presence of symptoms of 
anxiety if HADS- A ≥11 and presence of symptoms of 
depression if HADS- D ≥11.31
Statistical analysis
Categorical data were presented by its absolute and rela-
tive frequency while continuous data were presented 
using the median and quartiles of their distribution due 
to the lack of normality, evaluated by the Shapiro- Wilk 
test. Considering this, non- parametric testes were used to 
compare groups concerning continuous data, namely the 
Kruskal- Wallis test with pairwise comparisons adjusted 
for multiple comparisons whenever the categories of JIA 
were being compared. When statistically significant, these 
pairwise comparisons were then performed considering 
a reference category (persistent oligoarthritis JIA) using 
Benjamini- Hochberg correction with a false discovery 
rate of 20%, applied to p values of multiple comparisons.
To compare PROs between polyarticular course 
patients with JIA and RA and between ERA in adulthood 
and SpA, concerning continuous data the Mann- Whitney 
U test was used. For categorical data, the Fisher’s exact 
test was applied.
When the differences regarding disease duration and 
disease activity between polyarticular course patients with 
JIA and RA and ERA in adulthood and SpA were signif-
icant we applied analysis of covariance (ANCOVA) or 
two- way analysis of variance (ANOVA) models in order to 
adjust the results for these variables. Possible associations 
between age of the patient’s groups and PROs results 
were analysed using Spearman correlation.
Missing data were interpreted as random missing data. 
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A total of 585 patients with JIA were included in the study, 
whose main demographic and clinical features are shown 
in table 1.
The median age at the last registered visit was 28.6 
years (1–3 quartile: 21.8–38.6; range: 18–73) and median 
disease duration was 20.2 years (1–3 quartile: 12.8–29.6; 
range: 6–57). Most of the patients (85%) had disease for 
more than 10 years and 25% exceeded 30 years. JIA cate-
gories with polyarticular involvement and ERA were the 
most prevalent ones. Missing values of RF in RF positive 
polyarticular patients with JIA relate to the absence of 
the entrance of the value in  Reuma. pt but the attending 
physician have classified the patient based on the RF 
result registered in the hospital clinical record. RF posi-
tive polyarticular patients with JIA with a negative RF 
result registered were all ACPA positive.
This was a predominantly professionally active popula-
tion (78.6% of the patients employed), with a median 12 
years of education.
Thirty- eight per cent of the studied patients still had 
active disease, 51.6% were on a synthetic DMARD and 
35.9% on a biological DMARD. Only 35.8% of the 
patients with inactive disease were off medication. 66.9% 
of the patients had no or mild HAQ disability and 8.7% 
severe disability.
PROs—physical disability, mental health symptoms, fatigue 
and HRQoL—across JIA categories
Results of HAQ, anxiety and depression scores according 
to HADS, FACIT, EQ5D and SF- 36 in all domains, 
according to JIA ILAR categories are shown in table 2. Of 
the 585 patients with JIA included in the study, at the last 
visit registered, 551 had a registered HAQ, 210 HADS, 
227 FACIT- F, 181 EQ5D and 246 SF- 36.
Out of the 13 analysed PROs (HAQ, HADS depression 
and anxiety, FACIT- F, EQ5D and 8 domains of SF- 36), 
7 showed statistically significant differences across JIA 
categories by Kruskal- Wallis test. These included physical 
disability (HAQ), fatigue (FACIT- F) and HRQoL (EQ5D 
and the SF- 36 domains of physical function, role limita-
tions due to physical problems, intensity and discomfort 
caused by pain and social functioning).
Relative to persistent oligoarthritis, patients with 
undifferentiated arthritis had higher levels of physical 
disability (p=0.040) and fatigue (p=0.009), worse scores 
in EQ5D (p<0.001) and in the SF- 36 domains of physical 
function (p<0.001), role limitations due to physical prob-
lems (p=0.001), intensity and discomfort caused by pain 
(p<0.001) and social functioning (p=0.001).
As persistent oligoarthritis patients, patients with 
ERA had less fatigue reports than other categories of 
patients with JIA (figure 2), with a relevant difference 
when compared with patients with undifferentiated 
arthritis (median FACIT- F score in patients with ERA 
45 (39; 49.5) vs 34 (25; 40) in patients with undifferen-
tiated arthritis; p=0.045). Patients with ERA had also 
better results regarding HRQoL, with higher median 
EQ5D scores when compared with with systemic onset 
JIA (SoJIA) (0.69 (0.59; 1) in ERA vs 0.39 (0.29; 0.69) in 
SoJIA; p=0.029).
Figure 2 Patients’ physical disability (Health Assessment 
Questionnaire (HAQ) score) according to JIA category. (B). 
Fatigue (Functional Assessment of Chronic Illness Therapy, 
Fatigue Scale (FACIT- F) score) according to JIA category. 
(C). Health- related quality of life (EuroQol- 5D (EQ5D) score) 
according JIA category. Bars show the lower and upper 
quartiles; error bars show the range excluding outliers; 
horizontal lines within bars show the median; circles 
show outliers; asterisks show extreme values, triangles 
show significant pairwise comparisons (p<0.05) . ERA, 
enthesitis- related arthritis; Ext. oligo, extended oligoarthritis; 
JIA, juvenile idiopathic arthritis; Persist. oligo, persistent 
oligoarthritis; PsA, psoriatic arthritis; RF, rheumatoid 
factor; RF+ Poly., RF negative polyarthritis; RF- Poly., RF 
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Patients with persistent oligoarthritis and ERA had 
also significantly better scores in the physical compo-
nent of the SF- 36, when compared with patients with 
undifferentiated arthritis regarding physical function (90 
(70; 100) vs 40 (20; 75); p<0.001 and 0.69 (0.59; 1) vs 40 
(20; 75); p=0.003, respectively), role limitations due to 
Table 3 Sociodemographic, disease- related characteristics, physical disability, levels of depression, anxiety, fatigue and 
quality of life of the adult patients with JIA and patients with adult- onset rheumatic diseases
Variables
Patients with JIA 
with polyarticular 
involvement (n=245)
Control group of 
patients with RA 
(n=245) P value
Patients with ERA 
and JIA (n=110)
Control group of 
patients with SpA 
(n=110) P value
Female, n (%) 183 (74.7) 183 (74.7) 1.000 41 (38.3) 42 (38.2) 1.000
Age at the time of last registered 
visit, n (%)
          
18–39 years old 156 (62.4) 156 (62.4) 0.569 76 (69) 76 (69) 0.155
40–59 years old 76 (31.0) 76 (31.0) 0.095 27 (24.5) 27 (24.5) 0.426
≥60 years old 13 (5.3) 13 (5.3) 0.561 7 (6.4) 7 (6.4) 0.147
Disease duration, years (median 
(Q1; Q3))
21.59 (14.79; 31.18) 12.36 (8.52; 16.67) <0.001 15.76 (9.46; 26.69) 15.07 (10.36; 19.89) 0.414
Years of education (median (Q1; 
Q3))
12 (9; 14) 12 (7; 15) 0.251 12 (9; 15) 12 (9; 12) 0.591
Current professional situation, 
n (%)
          
Employed 114 (77) 143 (81.7) 0.728 55 (73.3) 76 (82.6) 0.287
Retired 8 (5.4) 7 (4) 0.621 2 (2.7) 4 (4.3) 0.568
Retired by disability 13 (8.8) 11 (6.3)   0.598 8 (10.7) 4 (4.3) 0.082
Unemployed 13 (8.8) 14 (8)   0.432 10 (13.3) 8 (8.7) 0.537
Active disease, n (%) 76 (42.5) 99 (41.5) 0.787 28 (34.1) 63 (59.4) <0.001
HAQ score (median (Q1; Q3)) 0.25 (0; 1) 0.63 (0.13; 1.13) < 0.001* 0 (0; 0.44) 0.75 (0; 1.5) 0.025†
HADS—depression symptoms, 
n (%)
7 (8) 8 (9.5) 0.075* 0 (0) 9 (14.8) 0.003†
HADS—anxiety symptoms, n (%) 8 (9.2) 16 (19) 0.080* 4 (9) 13 (21.3) 0.002†
FACIT- F (median (Q1; Q3)) 42 (33.5; 47) 40 (29; 47.5) 0.041* 45 (39; 49.5) 41 (29; 46) 0.01†
EQ5D (median (Q1; Q3)) 0.62 (0.4; 0.7) 0.58 (0.45; 0.77) < 0.001* 0.69 (0.59; 1) 0.66 (0.45; 0.7) 0.155†
EQ5D VAS (median (Q1; Q3)) 79 (50; 90) 15 (1; 37) < 0.001* 75 (50; 90) 20 (5; 48) 0.155†
SF- 36 PC           
PF (median (Q1; Q3)) 75 (50; 90) 72.22 (45; 95) < 0.001* 85 (55; 95) 80 (50; 90) 0.690†
RP (median (Q1; Q3)) 81.25 (25; 100) 75 (25; 100) < 0.001* 100 (50; 100) 75 (25; 100) 0.621†
BP (median (Q1; Q3)) 62 (41; 84) 62 (41; 79) < 0.001* 62 (42; 84) 62 (41; 74) 0.378†
GH (median (Q1; Q3)) 50 (35; 72) 43.5 (30; 61) < 0.001* 51 (37; 67) 45 (30; 57) 0.989†
SF- 36 MC           
VT (median (Q1; Q3)) 56.25 (40; 75) 50 (47.5; 55) < 0.001* 55 (45; 81.25) 50 (45; 62.5) 0.523†
SF (median (Q1; Q3)) 87.5 (62.5; 100) 62.5 (39.5; 100) < 0.001* 93.75 (62.5; 100) 75 (50; 100) 0.519†
RE (median (Q1; Q3)) 100 (58.33; 100) 100 (33.33; 100) < 0.001* 100 (100; 100) 91.67 (58.33; 100) 0.527†
MH (median (Q1; Q3)) 76 (61.4; 88) 69 (51.7; 86.5) < 0.001* 81.4 (64; 90) 72 (53.5; 82.7) 0.795†
Sample size regarding HAQ, HADS, FACIT- F, EQ5D and SF- 36 and other variables is not constant due to:
Years of education: JIA with polyarticular involvement n=139; control group of patients with RA n=150; ERA JIA n=70; control group of patients with SpA n=69.
Current professional situation: JIA with polyarticular involvement n=148; control group of patients with RA n=143; ERA JIA n=75; control group of patients with SpA 
n=76.
Active disease: JIA with polyarticular involvement n=179; control group of patients with RA n=238; ERA JIA n=82; control group of patients with SpA n=110.
HAQ score: JIA with polyarticular involvement n=242; control group of patients with RA n=199; ERA JIA n=88; control group of patients with SpA n=9.
HADS: JIA with polyarticular involvement n=87; control group of patients with RA n=84; ERA JIA n=44; control group of patients with SpA n=61
FACIT- F: JIA with polyarticular involvement n=96; control group of patients with RA n=84; ERA JIA n=48; control group of patients with SpA n=65
EQ5Ds score and VAS: JIA with polyarticular involvement n=77; control group of patients with RA n=108; ERA JIA n=38; control group of patients with SpA n=82.
SF- 36: JIA with polyarticular involvement n=99; control group of patients with RA n=160; ERA JIA n=50; control group of patients with SpA n=101.
*After adjustment for disease duration.
†After adjustment for disease activity.
. BP, intensity and discomfort caused by pain; EQ5D, EuroQol- 5D; ERA, enthesitis- related arthritis; FACIT- F, Chronic Illness Therapy, Fatigue Scale; GH, general 
health; HADS- A, Hospital Anxiety and Depression Scale—anxiety; HADS- D, Hospital Anxiety and Depression Scale—depression; HAQ, Health Assessment 
Questionnaire; JIA, juvenile idiopathic arthritis; SF36 MC, mental component of the Short Form 36; MH, mental health; ; SF36 PC, physical component of the Short 
Form 36; PF, physical function; RA, rheumatoid arthritis ; RE, role limitations due to emotional problems; RP, role limitations due to physical problems; SF, social 
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physical problems (100 (62.5; 100) vs 37.5 (25; 93.75); 
p=0.014 and 100 (50; 100) vs 37.5 (25; 93.75); p=0.018, 
respectively) and intensity and discomfort caused by 
pain (74 (62; 84) vs 51 (31; 62); p<0.001 and 62 (42; 84) 
vs 51 (31; 62); p=0.041). Patients with undifferentiated 
arthritis had also worse scores in physical function and 
role limitations due to physical problems domains when 
compared with patients with PsA (40 (20; 75) vs 97.5 
(90; 100); p=0.001 and 37.5 (25; 93.75); 100 (100; 100); 
p=0.011, respectively).
Of all patients with JIA, 10.5% and 4.8%, respectively, 
presented anxiety and depression symptoms (HADS 
score ≥11), however we found no differences regarding 
anxiety and depression levels between JIA categories.
Comparison of PROs (functional status, mental health 
symptoms, fatigue and HRQoL) between patients with JIA and 
adult-onset rheumatic diseases
For the group of patients with JIA with polyarticular 
involvement and ERA, respectively, 245 RA controls and 
110 SpA controls matched for sex and group ages, were 
selected from  Reuma. pt. The demographic and clinical 
characteristics of the patients with JIA and controls are 
summarised in table 3. Sixty- three per cent and 51.4% of 
patients with RA and 32.3% and 44.7% of the adult- onset 
SpA were on a synthetic or biological DMARD, respec-
tively.
After adjustment for disease duration, we found 
less disability in polyarticular patients with JIA when 
compared with patients with RA (median HAQ of 0.25 
(0; 1) in polyarticular course JIA vs 0.63 (0.13;1.13) in 
RA; p<0.001). Regarding depression and anxiety symp-
toms in these two groups of patients we did not find any 
differences. On the contrary we found that polyarticular 
course patients with JIA had better results than patients 
with RA regarding fatigue (FACIT- F scores 42 (33.5; 47) 
vs 40 (29; 47.5); p=0.041) and HRQoL, with better scores 
on EQ5D, both in self- reported problems and perceived 
health through Visual Analogue Scale (VAS) and all 
domains of SF- 36 (table 3).
Regarding patients with ERA and SpA, after adjustment 
for disease activity, we found that patients with ERA had 
less disability (median HAQ of 0 (0; 0.44) in ERA vs 0.75 
(0; 1.5) in patients with SpA; p=0.025), less depression 
and anxiety symptoms (0% vs 14.8%; p=0.003% and 9% 
vs 21.3%; p=0.002) and less fatigue symptoms (45 (39; 
49.5) vs 41 (29; 46); p=0.01) than patients with SpA. The 
differences in EQ5D and SF- 36 scores between patients 
with ERA and SpA, after adjustment for disease activity, 
were not found to be significant (table 3).
DISCUSSION
To the best of our knowledge, this is the only study of 
long- term follow- up of patients with JIA comparing 
mental health symptoms, fatigue and HRQoL across JIA 
categories and with adult- onset rheumatic diseases. This 
adult JIA population with a median disease duration of 
20.2 years (25% exceeding 30 years of disease duration) 
had a predominance of polyarticular and ERA categories, 
which reflects the JIA population that prevail in adult 
Rheumatology care. Most of these patients were still on 
a synthetical or biological DMARD and 38% had active 
disease, which is in line with the disease activity profile 
depicted in other long- term studies. Selvaag et al reported 
that 41% of the patients with JIA maintained disease 
activity after 30 years and other studies reported active 
disease in 37%–46% of the patients.6 14 33 Disease status 
varied according to JIA categories, with inactive disease 
most often seen in patients with persistent oligoarticular 
JIA and least often seen in RF- positive polyarticular JIA, 
as shown in previous studies.6 33 34
The degree of disability in our patients mirrored the 
ones found in other recent studies of adult outcomes in 
JIA. A decade ago JIA outcome studies described poorer 
functional outcomes, as in the Foster et al,3 study that 
found a median HAQ of 1.13 (0; 3) or the Packman et al14, 
that depicted severe disability in 42% of the patients. In 
our study, median HAQ was 0.13 (0; 0.8), with the worst 
functional outcome reported in RF positive polyarticular 
JIA. Only 8.7% of the patients had severe disability. Toll-
isen et al recently found even a lower percentage (3%) of 
patients with severe disability at 30- year follow- up.5
After adjustment for disease duration, we found less 
disability in patients with JIA when compared with patients 
with adult- onset rheumatic diseases. Studies comparing 
functional disability between adult patients with JIA with 
RA or SpA cohorts are scarce. To our knowledge there are 
only two studies evaluating physical disability in adult JIA 
and RA.35 36 Both studies, one from the pre- biological era 
and the other examining the differences between adult 
JIA and RA in the biologics era, found also better physical 
function in JIA than in patients with RA. In another study, 
135 juvenile patients with AS were compared with 135 
patients with adult- onset AS.37 The authors reported that 
functional impairment and disability were less marked 
in juvenile AS compared with adult- onset AS. In a more 
recent study also comparing juvenile and adult- onset AS, 
Stone et al found that juvenile patients with AS suffered 
more functional impairment compared with patients 
with adult- onset AS.38 However, the differences regarding 
the population selected and the measurements used to 
evaluate disability may account for the discrepancy in 
reported outcomes between studies.
This is the first study comparing depression and anxiety 
symptoms levels between JIA categories in adults and with 
adult- onset rheumatic diseases cohorts. We did not find 
differences among different JIA categories or between 
polyarticular patients with JIA and RA but patients with 
ERA had better results when compared with SpA, after 
adjustment for disease activity. Regarding depression 
and anxiety symptoms there are only studies comparing 
results in adult patients with JIA to the general popula-
tion and with contradictory findings. Barth et al found 
significantly higher rates of anxiety/depression in JIA 
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et al found that only 4.9% of the adults with JIA self- 
reported depression, significantly fewer compared with 
the general population.39 We found a similar percentage 
(4.8%) of adult patients with JIA who showed symptoms 
of depression and a higher number of patients with 
anxiety symptoms (10.5%). These results are in line with 
the ones found among the adult Portuguese population 
with rheumatic and musculoskeletal diseases (RMDs) 
in a national health- survey conducted to estimate the 
national prevalence of RMDs.12 When the subjects with 
and without RMDs regarding mental distress symptoms 
were compared, Branco et al found a significantly higher 
proportion of patients with RMD with anxiety symptoms 
but not with depressive symptoms, with a prevalence 
of 16.7% for anxiety and 8.3% for depression. In this 
population- based study, SpA was the only RMD associated 
with anxiety symptoms, which could help to explain our 
worse results in SpA when compared with patients with 
ERA.
In our study fatigue symptoms were also worse in adult- 
onset diseases than in JIA and when JIA categories were 
compared, patients with ERA were the ones with less 
fatigue reports. Fatigue symptoms were shown to predict 
lower physical HRQoL at long- term in patients with 
JIA5 and to be more common in adults with JIA when 
compared with healthy controls.40 However, there are 
no other studies comparing long- term fatigue outcomes 
between JIA categories or between adult patients with JIA 
and adult- onset rheumatic diseases.
PROs such as HRQoL have been found to vary 
across different JIA categories in previous studies, with 
persistent oligoarticular JIA having better outcomes 
when compared with other JIA categories.3 5 41 42 In our 
study we found that persistent oligoarthritis and patients 
with ERA had better scores in EQ5D and in the physical 
component of SF- 36, regarding physical function, role 
limitations due to physical problems and intensity and 
the discomfort caused by pain, than other categories 
of JIA. This difference was significant when compared 
with patients with undifferentiated arthritis who had 
the worst scores in all these domains. This was also true 
for the social functioning domain of the mental compo-
nent of SF- 36 in which patients with undifferentiated 
arthritis had worst scores when compared with all other 
categories. These results could be explained by the fact 
that these patients classified as having undifferentiated 
arthritis JIA were the ones with late disease onset and late 
diagnosis, were older than patients from other categories 
and had longer disease duration. In our previous study 
with a similar cohort we showed that 50% of undifferen-
tiated arthritis adult patients with JIA fulfilled criteria for 
RA,4 which could also help to explain these results.
Several studies analysing adult patients with JIA 
reported poorer physical functioning and perception 
of their health and more bodily pain when compared 
with age and sex matched controls.3 10 40 43 44 However, no 
study so far compared HRQoL from adult patients with 
JIA to age and sex matched patients having adult- onset 
rheumatic diseases as controls. We found that patients 
with JIA with polyarticular course had better HRQoL than 
control patients with RA, after adjustment for disease 
duration. This was true for the self- reported problems in 
EQ5D, perceived health trough VAS and all domains of 
SF- 36. In patients with ERA, who were older at disease 
onset, despite having better scores than patients with SpA 
in all domains of HRQoL, the significance of these differ-
ences were lost, after adjustment for disease activity. Less 
comorbidities or greater resilience of a younger body and 
mind could be explanations for generally better results 
in PROs from patients with JIA when compared with 
patients with RA and adult- onset SpA.
Our study has some limitations. First its cross- sectional 
design may not accurately estimate the evolution over 
time of functional status, mental health symptoms, 
fatigue and HRQoL in patients with JIA. As this is a long- 
term study the effect of different treatment strategies 
likely had also impact on some of these outcomes. In 
adult patients with ERA/SpA functional status would be 
measured in a more accurate way if we had used BASFI 
(Bath Ankylosing Spondylitis Functional Index) instead 
of HAQ. However, none of the instruments are validated 
in patients with ERA JIA. Additionally, selection bias of the 
registry may over- represent more severe cases and some 
categories of JIA, like the ones with polyarticular involve-
ment, as many patients in remission could have been 
lost for follow- up and patients with milder disease could 
have been less motivated to be enrolled and complete 
questionnaires. In fact, not every patient included in the 
study had completed all PROs at the last visit registered, 
which led to missing data that could have influenced the 
results. Information on uveitis and joint replacement was 
not included due to missing data. Therefore, their role in 
the PROs results cannot be analysed.
This study has also several strengths, as the long 
follow- up and the use of both EQ5D and SF- 36 to assess 
the HRQoL, which increased the consistency of the 
results regarding this outcome. It is also the first long- 
term study to compare outcomes regarding mental 
health symptoms and fatigue among JIA categories and 
mental health symptoms, fatigue and HRQoL in adult 
patients with JIA with age and sex matched patients with 
adult- onset rheumatic diseases.
In conclusion, our results document that persistent 
oligoarticular JIA and ERA are the categories with better 
HRQoL, namely in its physical component. Anxiety 
symptoms were more common than depression in 
patients with JIA, with similar results among different 
JIA categories. Adult patients with JIA with polyarticular 
course have less disability, fatigue and better HRQoL 
when compared with patients with RA but with similar 
frequency of anxiety and depression symptoms. Patients 
with ERA had less disability, less depression and anxiety 
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Overall adult polyarticular and ERA JIA have lower 
impact on function and on several quality of life- related 
aspects than RA and SpA.
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